Rhythm Pharmaceuticals In... (RYTM)

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants David Connolly - Head of Investor Relations & Corporate Communications David...

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.55 per share a year ago.

Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Smith Hunter C, Chief Financial Officer of Rhythm Pharmaceuticals (RYTM -0.04%), reported mixed transactions totaling 42,120 shares on July 9, 2025, as disclosed in an SEC Form 4 filing, resulting in ...

Rhythm Pharmaceuticals, Inc.'s IMCIVREE and new oral MC4R agonist, bivamelagon, show strong efficacy in rare obesity disorders, especially hypothalamic obesity (HO). HO represents a blockbuster market...

Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.

Rhythm Pharmaceuticals (RYTM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further streng...

Rhythm Pharmaceuticals shares surged to a record high Wednesday on promising results for a drug that could treat a rare form of obesity.

I maintain my Buy rating on Rhythm Pharmaceuticals due to its leadership in rare genetic obesity treatments. The company's innovative therapies address significant unmet needs, supporting long-term gr...

Rhythm stock is approaching its all-time high in a long base. Rhythm makes drugs to treat disorders due to genetic changes.